Джейн Плант - Ваша жизнь в ваших руках. Как понять, победить и предотвратить рак груди и яичников

3. Irwig, Les, 2006. Evaluating new screening tests for breast cancer. BMJ, 332, 678–679.

4. Anon, 2006. Screening for breast cancer. BMJ, 332, 499–500.

5. www.nlm.nih.gov/medineplus/ency/article/002919.htm

6. e.g. Baum, М., 2000. Survival and reduction in mortality from breast cancer – Impact of mammographic screening is hot clear (Letter). BMJ, 321, 1470.

7. Spurgeon, David, 2002. Annual mammography in women in their 40s does not cut death rate. BMJ, 325, 563.

8. Spurgeon, David, 2002. Annual mammography in women in their 40s does not cut death rate. BMJ, 325, 563.

9. Josefson, Deborah, 2002. Breast self-examination does not improve cancer survival. BMJ, 325, 793.

10. Zackrisson S. and others, 2006. Rare of over-diagnosis of breast cancer 15years after end of Malmo mammographic screening trial; follow up study. BMJ, 332, 689–692.

11. Anon, 2006. Screening for breast cancer. BMJ, 332, 499–500.

12. Symonds, R. Paul, 2002. Cancer biology may be more important than diagnostic delay. BMJ, 325, 774.

13. Spurgeon, David, 2002. Annual mammography in women in their 40s does not cut death rate. BMJ, 325, 563.

14. www.cancerscreening.nhs.uk/breastscreen

15. White, Caroline, 2002. ‘Unacceptable’ errors found in breast screening process. BMJ, 324, 933.

16. UK National Radiological Protection Board, www.nrpb.org/ radiation_topics/risks/exposure.htm

17. Irwig, Les, 2006. Evaluating new screening tests for breast cancer. BMJ, 332, 678–679.

18. www.well-connected.com/rreports/doc06full.html

19. www.well-connected.con’i/rreports/doc06full.html

20. Keyomarsi, K., Tucker, S.L., Buchholz, T.A., Callister, M., Ding, Y., Hortobagyi, G.N., Bedrosian, I. Knickerbocker, C., Toyofuku, W, Lowe, M., Herliczek, T.W, and Bacus, S.S., 2002. Cyclin E and Survival in Patients with Breast Cancer. N Engl J Med, 347, 1566–1575.

21. Yancik, R. and Ries, L.A., 1994. Cancer in older persons. Magnitude of the problem – how do we apply what we know? Cancer, 74 (7 Suppl), 1995–2003.

22. Silliman, R.A. and Baeke, P., 1998. Breast cancer in the older woman. In: Balducci, L., Ersher, W B. and Lyman, G.H., Comprehensive geriatric oncology. Amsterdam: Harwood.

23. Welch, H.G., Albertson, EC., Nease, R.E, Bubolz, T.A. and Wasson, J.H., 1996. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med, 124, 577–584.

24. Holmes, EE, 1994. Clinical course of cancer in the elderly. Cancer Control, 1, 108–114.

25. Nixon, A.J., Neuberg, D., Hayes, D.E, Gelman, R., Connolly, J.L., Schnitt, S. and others, 1994. Relationship of patient age to pathological features of the tumor and prognosis for patients with stage I or II breast cancer./ Clin Oncol, 12, 888–894.

26. Balducci, Lodovico and Phillips, D. Melissa. 1998. Breast cancer in older women. American Family Physician. October 1, 1998. www.aafp.org/afp/981001 ap/balducci.html

27. www.well-connected.com/rreports/doc06full.html

28. Medical Report: Prostate Cancer. ICON, 2002, 1 (5), 8-10.

29. Waxman, Jonathan, 2001. The Prostate Cancer Book. London: Vermillion.

30. http://www.nccn.org/paticnt_gls/_english/_prostate/

31. http://www.nccn.org/patient_gls/_english/_prostate/

32. Hart, D. and Wall, 2004. UK population dose from medical examinations. European Journal of Radiology, 50 (3), 285–291, Brenner, D.I. and others, 2001. CT scanning of children has been calculated 10 increase their lifetime risk of cancer. American Journal of Roentology, 176, 289–296.

33. http://www.nccn.org/patient_gls/_english/_prostate/

34. http://www.cancer.org

35. Spurgeon, David, 2003. Advanced scanning techniques help doctors stage prostate cancer. BMJ, 326, 1418.

36. New England Journal of Medicine, 2003, 348, 2491–2499.

37. http://www.nccn.org/patient_gls/_english/_prostate/

38. Fisher, B. and others, 2002. Twenty year follow-up of a randomised trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine, 347 (16), 1233–1241.

39. Fisher, B., Bryant, J., Dignam, J.J., Wickerham, D.L., Mamou-nas, E.F., Fisher, E.R., Margolese, KG., Nesbitt, L., Paik, S., Pisansky, T.M., Wolmark, N., 2002. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less./ Clin Oncol, 20 (20), 4141–4149; www.ncbi.nlm.nih.gov; 80

40. Fisher, B., Anderson, S., Bryant, J., Margolese, R.G., Deutsch, M., Fisher, E.R., Jeong, J.H. and Wolmark, N., 2002. Twenty-year follow-up of a randomised trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 347 (16), 1233–1241; www.ncbi.nlm.nih.gov; 80

41. Gottlieb, Scott. Lumpectomy is as effective as mastectomy for breast cancer. BMJ, 325, 921.

42. www.nlm.nih.gov/medlineplus/ency/article/002919.htm

43. www.nlm.nih.gov/medlineplus/ency/article/002919. htm

44. www.cancer.org/docroot/cri/content/cri_2_6x_breast_recon-struction_after_mastectomy_5.asp

45. Bartelinkh and others, 2001. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. New England J Med, 345 (19), 1378–1387.

46. http://cis.nci.nih.gov/fact/7_l6.htm

47. Morrow, Monica and Gradishar, William, 2002. Recent Development: Breast Cancer. BMJ, 324, 410–414.

48. Coombes, R.C. and others, 2006. American Society of Clinical Oncology, Annual Meeting, Atlanta Georgia, June 2006.

49. Gralow, Julie R., 2002. Bisphosphonates as adjuvant treatment for breast cancer. BMJ, 325, 1051–1052.

50. www.gene.com/gene/products/information/oncology/ herceptin;

www.herceptin.com/herceptin/ physician/pi.htm

51. www.herceptin.com/herceptin/physician/pi.htm

52. Anon, 2006. Patient is to appeal High Court ruling on breast cancer drug. BMJ, 332–443.

53. Barrett, A. and others, 2006. How much will herceptin really cost? BMJ, 333, 1118–1120.

54. Daily Mail, Monday, 9 October, 2006.

55. www.ahrq.gOv/news/press/pr2002/brchempr.htm

56. http://cis.nci.nih.gov/fact/7_ 16.htm

56. http://cis.nci.nih.gov/fact/ 7_16. htm

57. Gottlieb, Scott, 2002. Tamoxifen may increase risk of uterine sarcoma, BMJ, 325, 7.

58. http://cis.nci.nih.gov/fact/7_16. htm

59. Mayor, Susan, 2002. Anastrozole shows promise for early breast cancer. BMJ, 324, 1539

60. www.gene.com/gene/products/information/oncology/hercep-tin;

www.herceptin.com/herceptin/physician/pi.htm

61. http://cis.nci.nih.gov/fact/7_45. htm

62. www.ahrq.gov/news/press/pr2002/brchempr.htm

63. New Scientist, 20 January, 2007.

64. Editorial, New Scientist, 31 March, 2007.

65. Josefson, Deborah, 2002. Doctors warned to be wary of new drugs. BMJ, 324, 1113.

66. Garattini, Silvio and Bertele, Vittorio, 2002. Efficacy, safety, and cost of new anticancer drugs. BMJ, 325, 269–271.

67. www.cancer.gov

68. Modified after: Chemotherapy and You: A Guide to Self-Help During Cancer Treatment. Information about what to expect during chemotherapy and what patients can do to take care of themselves during and after treatment NIH Publication #99-1136: www.cancer.gov/cancerinfo/chemorherapy-and-you

69. Smith, I. and Chue, S., 2006. Medical treatment of early breast cancer. BMJ, 332, 162–181.

70. Allison, R. and others, 2006.Photodiagnosis and photodynamic therapy, 3, 139–146.

71. Fritsch, С. and Ruzika, Т., 2003. Fluorescence diagnosis and photodynamic therapy of skin diseases atlas and handbook. Vien: Springer-Verlag.

72. Coulter; Angela, 2003. Killing the goose that laid the golden egg. BMJ, 326, 1280.

73. Coulter, Angela, 2003. Killing the goose that laid the golden egg. BMJ, 326, 1280.

74. Ernst, E., 2003. Herbal medicines put into context. BMJ, 327, 881–882.

75. Waxman, Jonathan, 2001. The Prostate Cancer Book. London: Vermillion.

76. Dyer, Owen, 2003. Aspirin could be used to prevent cancer. BMJ, 326, 565.

77. Flower, Rod, 2003. What are all the things that aspirin does? BMJ, 327, 572–573.

78. UK limits use of aspirin by under 16s. BMJ, 2002, 324, 1294.

79. Astralagus. ICON, 2002, 1 (3), 23.

80. Bartram, Т., 1998. Bartram’s encyclopedia of herbal medicine. Robinson publishing.

81. Campbell, T.C. and Campbell, T.M., 2006. The China Study. Benbella Books.

82. Greenwald, Peter, 2002. Cancer chemoprevention. BMJ, 324, 714–718.

1. Clarke, M.F. and Becker, M.W, 2006. Stem cells: the real culprits in cancer? Scientific American, July 2006, 53–59.

2. Study reveals how growth factors affect human stem cells. www.hhmi.org/news/melton.hmtl

3. Murray, R.K., Granner, D.K., Mayes, P.A. and Rodwell, VW, 1990. Harper's Biochemistry. Appleton and Lange Norwalk, CT, p. 653.

4. Woolf, Neville, 1998. Pathology, Basic and Systemic. WB. Saunders Publishing Co., Chapter 28, p. 274, Figure 28.

5. www.intouchlive.com/cancergenetics/onco.htm

6. Ludwig, Т., Fisher, P., Ganesan, S. and Efstratiadis, 2001. Tum-origenesis in mice carrying a truncating BRCA1 mutation. Genes and Development, Vol. 15 (10), 1188–1193.

7. Xu, X., Wagner, K.U., Larson, D., Weaver, Z., Li, C., Ried, Т., Hennighausen, L., Wynshaw-Boris, A. and Deng, C.X. 1999. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, Vol. 22 (1), 37–43.

8. Pauli, T.T, Cortez, D., Bowers, B., Elledge, S.J. and Geliert, M., 2001. Direct DNA binding by BRCA1. Proceedings of the National Academy of Sciences of the USA, Vol. 98 (11), 6086–6091.

9. Jensen, R.A., Thompson, M.E., Jetton, T.L., Szabo, C.I., van der Meer, R., Helou, В., Tronick, S., King, M.C., Page, D.L. and Holt, J.T., 1996. BRCA1 is secreted and exhibits properties of a granin. Nature Genetics, 12, 303–308; www.mc.vander-bilt.edu/cancer/research/ roster/jensen.html

10. Struewing, J.P., Abeliovich, D., Peretz, Т., Avishai, N., Kaback, M.M., Collins, F.S. and Brody, L.C., 1995. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi-Jewish individuals. Nature Genetics, 11, 198–200;

http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html

11. Roa, B.B., Boyd, A.A., Volcik, K. and Richards, C.S., 1996. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14, 185–187; Oddoux, C., Struewing, J.P., Clayton, C.M., Neuhausen, S., Vrody, L.C., Kaback, M., Haas, B., Norton, L., Borgen, P., Jhanwar, S., Golgar, D., Ostrer, H. and Offit, K., 1996. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %. Nature Genetics, 14, 188–190; http://rex.nci.nih.gov/massmedia/back-grounders/ashkenazi.html

12. www.mercola.com/2002/apr/27/sv40.htm

13. Hursting, S.D., Slaga,T.J., Fischer, S.M., DiGiovanni, J. and Phtans, J. M., 1999. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. Journal of the National Cancer Institute, 35, 2031–2038.

14. Cheeseman, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.

15. Cheesernan, K.H. and Slater, T.F., 1993. Free Radicals in Medicine. Churchill Livingston.

16. Stewart, H.J., 1989. Clinical experience in the use of antioestrogen tamoxifen in the treatment of breast cancer. Proceedings of the Royal Society of Edinburgh, 95B, 231–237.

17. Miller, W R., 1997. Aromatase inhibitors and breast cancer. Cancer Treatment Reviews, 23, 113–131.

18. Dao, T.L., Sinha, D.K., Nemato, T. and Patel, J., 1982. Effects of estrogens and progesterone on cellular replication of human breast tumours. Cancer Research, 42, 359–362.

19. Conte, P.P., Fraschini, G. and Dewinko, B., 1985. Estrogen induced expansion of the growth fraction in receptor negative human breast cancer.Journal of Steroid Biochemistry, 23, 1169–1172.

20. Miller, WR. and Langdon, S.P., 1997. Hormonal, growth factor and cytokine control of breast cancer. In: Biology of Female Cancers, pp. 43–60. Langdon, S,P., Miller, WR. and Berchuck, A. (editors). New York: CRC Press.

21. Miller, WR., 1991. Oestrogens and breast cancer: biological considerations, British Medical Bulletin, 47, 470–483.

22. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

23. Rose, Steven, with Mileusnic, Radmila, 1999. The Chemistry of Life. Fourth (revised) edition. Penguin Books.

24. Voet, Donald and Voet, Judith, 1995. Biochemistry. Second edition. John Wiley & Sons, Inc.

25. Jiang, Wen G., Matsumoto, Kunio and Nakamura, Toshikazu (editors), 2001, Growth Factors and their Receptors in Cancer Metastasis. Dordrecht: Kluwer Academic Publishers.

26. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

27. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

28. www.ucop.edu/srphome/bcrp/progressreport/abstracts/ innov/3CB-0186.html

29. Yu, H. and Rohan, Т., 2002. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92, 1472–1489.

30. www.preventcancer.com/pdf/InsulinGrowth266.html

1. www.dep.iarc.fr/globocan/database.pdf